UA73475C2 - Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis - Google Patents

Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis Download PDF

Info

Publication number: UA73475C2
Authority: UA; Ukraine
Prior art keywords: polypeptide; virus; hepatitis; amino acid; nucleic acid
Prior art date: 1998-06-19

Application number

UA2000127296A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Government Of Republic Singapo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-19

Filing date

1998-06-19

Publication date

2005-08-15

1998-06-19 Application filed by Government Of Republic Singapo filed Critical Government Of Republic Singapo

2005-08-15 Publication of UA73475C2 publication Critical patent/UA73475C2/uk

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 299
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 247
229920001184 polypeptide Polymers 0.000 title claims abstract description 245
241000700721 Hepatitis B virus Species 0.000 title claims abstract description 197
238000000034 method Methods 0.000 title claims abstract description 84
108091034117 Oligonucleotide Proteins 0.000 title claims description 48
150000001875 compounds Chemical class 0.000 title claims description 45
229960005486 vaccine Drugs 0.000 title claims description 38
239000000203 mixture Substances 0.000 title claims description 30
239000013598 vector Substances 0.000 title claims description 27
208000015181 infectious disease Diseases 0.000 title claims description 22
238000012216 screening Methods 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title description 8
208000006454 hepatitis Diseases 0.000 title description 5
231100000283 hepatitis Toxicity 0.000 title description 5
239000007788 liquid Substances 0.000 title description 3
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 title 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 173
150000007523 nucleic acids Chemical class 0.000 claims abstract description 130
108020004707 nucleic acids Proteins 0.000 claims abstract description 126
102000039446 nucleic acids Human genes 0.000 claims abstract description 126
101710084021 Large envelope protein Proteins 0.000 claims abstract description 92
239000004475 Arginine Substances 0.000 claims abstract description 89
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 89
239000004471 Glycine Substances 0.000 claims abstract description 87
239000002773 nucleotide Substances 0.000 claims abstract description 52
125000003729 nucleotide group Chemical group 0.000 claims abstract description 52
150000001413 amino acids Chemical group 0.000 claims abstract description 51
230000003612 virological effect Effects 0.000 claims abstract description 20
238000004113 cell culture Methods 0.000 claims abstract description 9
125000003275 alpha amino acid group Chemical group 0.000 claims description 156
108091007433 antigens Proteins 0.000 claims description 65
102000036639 antigens Human genes 0.000 claims description 64
239000000427 antigen Substances 0.000 claims description 63
125000000539 amino acid group Chemical group 0.000 claims description 47
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 45
241000700605 Viruses Species 0.000 claims description 31
108020004999 messenger RNA Proteins 0.000 claims description 28
238000001514 detection method Methods 0.000 claims description 18
108020004414 DNA Proteins 0.000 claims description 17
210000002966 serum Anatomy 0.000 claims description 16
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 15
101710123661 Venom allergen 5 Proteins 0.000 claims description 15
206010073069 Hepatic cancer Diseases 0.000 claims description 14
206010073071 hepatocellular carcinoma Diseases 0.000 claims description 14
201000002250 liver carcinoma Diseases 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 12
210000004369 blood Anatomy 0.000 claims description 11
239000008280 blood Substances 0.000 claims description 11
238000002955 isolation Methods 0.000 claims description 11
230000027455 binding Effects 0.000 claims description 10
239000003550 marker Substances 0.000 claims description 9
210000001124 body fluid Anatomy 0.000 claims description 7
239000010839 body fluid Substances 0.000 claims description 7
230000003321 amplification Effects 0.000 claims description 6
208000002672 hepatitis B Diseases 0.000 claims description 6
238000009396 hybridization Methods 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000009870 specific binding Effects 0.000 claims description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
230000003053 immunization Effects 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
238000000746 purification Methods 0.000 claims description 5
201000009030 Carcinoma Diseases 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
230000000890 antigenic effect Effects 0.000 claims description 4
238000002649 immunization Methods 0.000 claims description 4
210000004185 liver Anatomy 0.000 claims description 4
230000002285 radioactive effect Effects 0.000 claims description 4
210000001519 tissue Anatomy 0.000 claims description 4
238000013519 translation Methods 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
239000002671 adjuvant Substances 0.000 claims description 3
230000009918 complex formation Effects 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
238000013518 transcription Methods 0.000 claims description 3
230000035897 transcription Effects 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
239000002299 complementary DNA Substances 0.000 claims description 2
229960002520 hepatitis vaccine Drugs 0.000 claims description 2
230000016784 immunoglobulin production Effects 0.000 claims description 2
241000239366 Euphausiacea Species 0.000 claims 2
229940126601 medicinal product Drugs 0.000 claims 2
238000012876 topography Methods 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 abstract description 31
102000004169 proteins and genes Human genes 0.000 abstract description 28
239000000470 constituent Substances 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 description 54
229940024606 amino acid Drugs 0.000 description 52
239000000523 sample Substances 0.000 description 29
235000018102 proteins Nutrition 0.000 description 27
230000000295 complement effect Effects 0.000 description 18
230000035772 mutation Effects 0.000 description 18
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
231100000350 mutagenesis Toxicity 0.000 description 15
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
108020005202 Viral DNA Proteins 0.000 description 11
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
108091008146 restriction endonucleases Proteins 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 8
239000000463 material Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000010367 cloning Methods 0.000 description 6
239000003814 drug Substances 0.000 description 6
108010067390 Viral Proteins Proteins 0.000 description 5
239000000074 antisense oligonucleotide Substances 0.000 description 5
238000012230 antisense oligonucleotides Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003443 antiviral agent Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000000032 diagnostic agent Substances 0.000 description 4
229940039227 diagnostic agent Drugs 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
101710173438 Late L2 mu core protein Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
229940021993 prophylactic vaccine Drugs 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000011895 specific detection Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
229940021747 therapeutic vaccine Drugs 0.000 description 3
230000014616 translation Effects 0.000 description 3
101710132601 Capsid protein Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
101710175243 Major antigen Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
-1 antibody Proteins 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000000945 filler Substances 0.000 description 2
229940060415 hepatitis b immune globulin Drugs 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
206010059193 Acute hepatitis B Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
101000609447 Beet necrotic yellow vein virus (isolate Japan/S) Protein P25 Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101100078424 Caenorhabditis elegans mtrr-1 gene Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
102100027988 GTP-binding protein Rhes Human genes 0.000 description 1
101000578396 Homo sapiens GTP-binding protein Rhes Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241001387976 Pera Species 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102100021941 Sorcin Human genes 0.000 description 1
101710089292 Sorcin Proteins 0.000 description 1
108010015780 Viral Core Proteins Proteins 0.000 description 1
101150003160 X gene Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
238000011451 sequencing strategy Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000005570 vertical transmission Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
General Engineering & Computer Science (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Toxicology (AREA)
Pathology (AREA)

UA2000127296A 1998-06-19 1998-06-19 Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis UA73475C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/SG1998/000045 WO1999066047A1 (en)	1998-06-19	1998-06-19	A vaccine-induced hepatitis b viral strain and uses thereof

Publications (1)

Publication Number	Publication Date
UA73475C2 true UA73475C2 (en)	2005-08-15

Family

ID=20429861

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000127296A UA73475C2 (en)	1998-06-19	1998-06-19	Hepatitis b virus strain, induced by vaccine, nucleic acid isolated molecule coding mutant main surface antiigen of hepatitis b virus, vector and vector system for the preparation of polypeptide, a method for the preparation of polypeptide (variants), purified polypeptide (variants), oligonucleotide, a method for the preparation of antibodies (variants), antibody (variants), a method for the determination of chemical compound for treating the infection of hepatitis b strain infection, a composition, a method for the preparation of composition, a method of organism liquids screening for hepatitis b virus, a method of antibody use, vaccine against hepatitis

Country Status (22)

Country	Link
US (2)	US7038035B1 (no)
EP (1)	EP1086232A1 (no)
JP (1)	JP2002518013A (no)
KR (1)	KR100498117B1 (no)
CN (1)	CN1255540C (no)
AR (1)	AR020092A1 (no)
AU (1)	AU756858B2 (no)
BG (1)	BG105065A (no)
BR (1)	BR9815912A (no)
CA (1)	CA2332173A1 (no)
HU (1)	HUP0103258A3 (no)
IL (1)	IL140363A0 (no)
IS (1)	IS5777A (no)
MX (1)	MXPA00012724A (no)
MY (1)	MY135991A (no)
NO (1)	NO20006457L (no)
NZ (1)	NZ508892A (no)
PL (1)	PL191312B1 (no)
TR (1)	TR200003778T2 (no)
UA (1)	UA73475C2 (no)
WO (1)	WO1999066047A1 (no)
YU (1)	YU80500A (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP967999A0 (en) *	1999-04-09	1999-05-06	North Western Health Care Network	Viral variants
AUPQ810900A0 (en)	2000-06-09	2000-07-06	Austin and Repatriation Medical Centre, The	Viral variants and methods of using same
CN100355777C (zh) *	2003-02-10	2007-12-19	文洪模	乙型肝炎病毒pre－S突变蛋白及其制备方法与应用
US20060057670A1 (en) *	2004-09-10	2006-03-16	The Chinese University Of Hong Kong	Genomic markers of hepatitis B virus associated with hepatocellular carcinomas
CA2580620C (en)	2004-09-22	2014-04-22	Advanced Life Science Institute, Inc.	Method of detecting hepatitis b virus s antigen
TW200643171A (en) *	2005-06-07	2006-12-16	Temasek Life Sciences Lab Ltd	Porcine circovirus type 2 vaccines
CN101948933B (zh) *	2010-07-22	2013-04-03	中国人民解放军第三〇二医院	检测石蜡包埋肝组织乙型肝炎病毒cccDNA的试剂盒
CN101948932B (zh) *	2010-07-22	2013-04-03	中国人民解放军第三〇二医院	滚环扩增加跨缺口荧光定量PCR检测乙型肝炎病毒cccDNA试剂盒
RU2603729C2 (ru) *	2015-04-24	2016-11-27	Закрытое акционерное общество научно-производственная компания "Комбиотех"	Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2586513C1 (ru) *	2015-04-24	2016-06-10	Закрытое акционерное общество научно-производственная компания "Комбиотех"	РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ МУТАНТНОГО ПОВЕРХНОСТНОГО АНТИГЕНА ВИРУСА ГЕПАТИТА В (ВАРИАНТЫ)
EP4458975A3 (en)	2019-09-30	2025-02-12	Gilead Sciences, Inc.	Hbv vaccines and methods treating hbv
CN113201051B (zh) *	2021-04-27	2022-08-02	复旦大学	一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9007024D0 (en) *	1990-03-29	1990-05-30	Imperial College	Novel vaccine
US5955089A (en) *	1993-04-20	1999-09-21	Uab Research Foundation	Strain selection of pneumococcal surface proteins
GB9401987D0 (en) *	1994-02-02	1994-03-30	Imperial College	Modified nucleic acid
US5830759A (en) *	1994-08-18	1998-11-03	The Trustees Of Columbia University In The City Of New York	Unique associated Kaposi's sarcoma virus sequences and uses thereof
AU4353897A (en)	1996-09-18	1998-04-14	Board Of Regents, The University Of Texas System	Viral defective interfering particles and uses thereof

1998
- 1998-06-19 HU HU0103258A patent/HUP0103258A3/hu not_active Application Discontinuation
- 1998-06-19 KR KR10-2000-7014443A patent/KR100498117B1/ko not_active Expired - Fee Related
- 1998-06-19 PL PL345203A patent/PL191312B1/pl not_active IP Right Cessation
- 1998-06-19 TR TR200003778T patent/TR200003778T2/xx unknown
- 1998-06-19 NZ NZ50889298A patent/NZ508892A/xx unknown
- 1998-06-19 US US09/719,533 patent/US7038035B1/en not_active Expired - Fee Related
- 1998-06-19 MX MXPA00012724A patent/MXPA00012724A/es unknown
- 1998-06-19 JP JP2000554856A patent/JP2002518013A/ja active Pending
- 1998-06-19 CA CA002332173A patent/CA2332173A1/en not_active Abandoned
- 1998-06-19 CN CNB988142007A patent/CN1255540C/zh not_active Expired - Fee Related
- 1998-06-19 AU AU77950/98A patent/AU756858B2/en not_active Ceased
- 1998-06-19 WO PCT/SG1998/000045 patent/WO1999066047A1/en not_active Ceased
- 1998-06-19 EP EP19980926022 patent/EP1086232A1/en not_active Withdrawn
- 1998-06-19 BR BR9815912A patent/BR9815912A/pt not_active Application Discontinuation
- 1998-06-19 UA UA2000127296A patent/UA73475C2/uk unknown
- 1998-06-19 IL IL14036398A patent/IL140363A0/xx unknown
- 1998-06-19 YU YU80500A patent/YU80500A/sh unknown
1999
- 1999-06-17 MY MYPI99002505A patent/MY135991A/en unknown
- 1999-06-18 AR ARP990102961 patent/AR020092A1/es unknown
2000
- 2000-12-18 NO NO20006457A patent/NO20006457L/no not_active Application Discontinuation
- 2000-12-18 BG BG105065A patent/BG105065A/xx unknown
- 2000-12-19 IS IS5777A patent/IS5777A/is unknown
2006
- 2006-03-20 US US11/385,013 patent/US20070026422A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1255540C (zh)	2006-05-10
NO20006457D0 (no)	2000-12-18
AU756858B2 (en)	2003-01-23
WO1999066047A1 (en)	1999-12-23
AU7795098A (en)	2000-01-05
YU80500A (sh)	2004-05-12
IS5777A (is)	2000-12-19
MXPA00012724A (es)	2003-02-10
NO20006457L (no)	2001-02-16
CN1304453A (zh)	2001-07-18
KR20010106128A (ko)	2001-11-29
MY135991A (en)	2008-07-31
AR020092A1 (es)	2002-04-10
KR100498117B1 (ko)	2005-07-01
BG105065A (en)	2001-09-28
CA2332173A1 (en)	1999-12-23
HUP0103258A2 (hu)	2001-12-28
BR9815912A (pt)	2002-02-05
NZ508892A (en)	2004-02-27
US20070026422A1 (en)	2007-02-01
EP1086232A1 (en)	2001-03-28
PL191312B1 (pl)	2006-04-28
HUP0103258A3 (en)	2003-10-28
PL345203A1 (en)	2001-12-03
TR200003778T2 (tr)	2001-06-21
IL140363A0 (en)	2002-02-10
JP2002518013A (ja)	2002-06-25
US7038035B1 (en)	2006-05-02

Publication	Publication Date	Title
KR100217483B1 (ko)	1999-09-01	C형 간염 바이러스 에피토프
KR0185373B1 (ko)	1999-05-01	Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
JP2662358B2 (ja)	1997-10-08	Ｎａｎｂｖの診断用薬
KR100193801B1 (ko)	1999-06-15	진단 및 치료용 c형 간염 바이러스(hcv) 게놈서열
US5879904A (en)	1999-03-09	Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
WO1991004262A1 (en)	1991-04-04	New hcv isolates
EP0476130B1 (en)	2008-07-09	Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof
EP0700441B1 (en)	2004-08-25	Multiple sclerosis virus
WO1994018217A1 (en)	1994-08-18	Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
KR19990022114A (ko)	1999-03-25	추출되어 미처리된 폴리펩타이드를 사용하는 양성 스트랜드 ｒｎａ 바이러스의 진단 및 이에 대한 백신화 방법
US7038035B1 (en)	2006-05-02	Vaccine-induced hepatitis B viral strain and uses thereof
JP4641695B2 (ja)	2011-03-02	新規なｈｅｖ抗原性ペプチド及び方法
EP1212423B1 (en)	2009-01-07	Identification of the domain of plasmodium falciparum erythrocyte membrane protein 1 (pfemp1) that mediates adhesion to chondroitin sulfate a
KR20020008172A (ko)	2002-01-29	Ττ바이러스 서열 유래의 펩티드 및 ττ바이러스에결합하는 단일특이적 항체
US5866139A (en)	1999-02-02	Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
US7105165B2 (en)	2006-09-12	Mutant human hepatitis B viral strain and uses thereof
AU756866B2 (en)	2003-01-23	A mutant human hepatitis B viral strain and uses thereof
KR100187483B1 (ko)	1999-05-01	Hcv 폴리뉴클레오티드 및 그 사용
RU2270863C2 (ru)	2006-02-27	Мутантный штамм вируса гепатита в и его применение
EP0554624A1 (en)	1993-08-11	Oligonucleotides, oligopeptides and determination system of HCV antibody subtype
WO1994011737A1 (en)	1994-05-26	Method for detection of a new marker associated with hepatitis delta virus infection
NZ528350A (en)	2005-06-24	A vaccine-induced hepatitis B viral strain and uses thereof
NZ528739A (en)	2005-07-29	A mutant human hepatitis B viral strain and uses thereof